demonstrate elevated blood pressure, cardiac hypertrophy, glucose intolerance, and insulin resistance compared with age-matched WistarKyoto rats (WKY). We investigated concurrent effects of captopril on blood pressure, cardiac mass, myocardial enzyme activities, glucose tolerance, and insulin action in young male SHR. At 10 weeks of age, SHR were randomized into two groups, one receiving distilled water, the other a captopril solution (50 mg/kg body weight/day). We also examined age-matched WKY receiving distilled water. Blood pressure was measured by tail-cuff during the 4-week treatment period and oral glucose tolerance was tested at the end of treatment. Hearts were weighed and ventricular tissue was assayed for activities of 3-hydroxyacylCoA dehydrogenase, citrate synthase, and hexokinase. Growth rates were similar between captopril-treated and control SHR, but less than those of WKY. Captopril reduced blood pressure (134 ؎ ؎ 8 v 177 ؎ ؎ 8 mm Hg, P < < .05) and left ventricular mass (؊ ؊18%, P < < .05) in SHR. Cardiac enzyme activities also changed with captopril treatment, reflecting an increased capacity for ␤-oxidation of fatty acids and reduced potential for glucose phosphorylation in the left ventricle of SHR. Serum concentrations of glucose, insulin, and free fatty acids after a brief fast and in response to oral glucose were not different after captopril treatment, suggesting no improvement in insulin action or glucose tolerance. In summary, treatment of young male SHR with captopril reduces blood pressure and cardiac mass, and promotes a small but significant increase in cardiac capacity for oxidation of fatty acids and reduction of glucose phosphorylation. In contrast, metabolic effects of captopril on oral glucose tolerance and insulin action were not evident. Am J Hypertens 1999; 12:581-589
P harmacologic treatment of patients with hypertension is complicated by the coexistence of multiple cardiovascular and metabolic disorders. For example, hypertension has been identified as an important precursor of left ventricular hypertrophy and a risk factor for cardiac failure. 1 In addition, we 2 and others 3 have demonstrated an association among hypertension, glucose intolerance, and impaired insulin-stimulated glucose uptake. This relationship occurs both in humans with essential hypertension 4 and in the spontaneously hypertensive rat, 2 and may reflect impaired insulin action in peripheral tissues such as skeletal muscle 5 and fat. 6 Patients and laboratory rats with hypertension also tend to have dyslipidemia compared with their normotensive controls. 2, 3 Furthermore, hypertension and its associated cardiac hypertrophy reportedly induces a shift in myocardial energy metabolism from oxidative catabolism of fatty acids to use of glucose 7, 8 and increases in cardiac glucose uptake are correlated positively with systolic blood pressure. 9 Angiotensin converting enzyme (ACE) inhibitors are an important class of drugs for treatment of patients with essential hypertension. Captopril was the first ACE inhibitor approved for use in patients and has been shown repeatedly to reduce systolic blood pressure in subjects with essential hypertension 10 -12 and spontaneously hypertensive rats. 13, 14 In addition to hemodynamic improvements, captopril can also alter cardiac structure and promote a therapeutic reduction of left ventricular hypertrophy. 14, 15 There is also some evidence in human subjects with essential hypertension that captopril improves insulin action, in vivo, 11 although this is not a universal finding. 16, 17 Effects of captopril treatment on cardiac substrate use are unknown, and this information may have important implications about overall cardiac performance. Given that the spontaneously hypertensive rat (SHR) demonstrates insulin resistance similar to that in human essential hypertension and marked cardiac enlargement at an early age, the aim of this study was to simultaneously evaluate effects of captopril treatment on several parameters. We asked the following questions: 1) Does administration of captopril improve insulin resistance, as well as reduce blood pressure? and 2) Does captopril treatment affect myocardial enzyme activities reflective of energy metabolism after cardiac regression?
MATERIALS AND METHODS
Experimental Animals and Treatments Adolescent (9-week-old) male SHR and normotensive rats from the parent Wistar-Kyoto strain (WKY) were purchased from Taconic Farms (Germantown, NY). Animals were maintained on a 12-h light-dark cycle and given access to standard laboratory chow and distilled water ad libitum. After 1 week of acclimation in the VA Northern California Health Care System Animal Research Facility, SHR were randomly assigned to untreated or captopril-treated groups for 4 weeks. Acclimation included handling and blood pressure measurement to habituate the animals to these maneuvers. SHR receiving captopril drank a solution (0.5 mg/mL distilled water) of the drug and, given our preliminary consumption data (100 mL/kg body weight each day), this resulted in approximately a 50 mg/kg body weight daily dosing. As an additional control, we also examined age-matched WKY rats receiving just distilled water to drink. Captopril was a gift from Bristol-Myers Squibb (Princeton, NJ) and solutions were made fresh daily. Animals were housed individually in metabolic cages (Hoeltge, Cincinnati, OH) to confirm captopril dosing. Animals were weighed and had blood pressure measured regularly once or twice a week during the treatment period. These studies were approved by the Animals Studies Subcommittee of the VA Northern California Health Care System.
Blood Pressure Measurements
Systolic blood pressure was measured in conscious, resting animals, as described previously, 2 using the tail-cuff method with an electrosphygmograph (Model 29 amplifier and sensors, IITC, Woodland Hills, CA). The validity of this method has been established 18 and our measurement system was calibrated weekly using an aneroid sphygmomanometer. Just before blood pressure measurements, rats were placed in acrylic holders (Model 82, IITC) and maintained at 28°C for 30 min. To assess drug impact, mid-morning blood pressure was determined throughout the treatment interval. At each time point, two systolic blood pressure measurements were taken on each animal and averaged.
Oral Glucose Tolerance Testing After 4 weeks of treatment, food was withdrawn from all animals at 8 am. At 1 pm, animals were weighed, the tail vein was nicked with a scalpel, and 500 L of blood was withdrawn for baseline analyses. Hemostasis was accomplished by application of silver nitrate to the tip of the tail. Blood was allowed to clot on ice, centrifuged, serum aspirated, and stored at Ϫ70°C until assayed. Glucose (1.75 g/kg body weight) was given by gavage as described elsewhere 2 and additional blood samples (500 L each) were obtained after 30 and 60 min. We chose this number of samples to minimize hemodynamic instability due to excessive blood loss. All samples from a given animal were assayed in duplicate at the same time. Serum glucose and free (nonesterified) fatty acids (FFA) were measured spectrophotometrically using commercially available kits purchased from Sigma (St. Louis, MO) and Wako (Richmond, VA), respectively. Serum insulin was determined by radioimmunoassay, using a kit obtained from Linco (St. Charles, MO).
Tissue Collection and Biochemical Assays of Myocardial Enzyme Activities
Following completion of the oral glucose tolerance test, animals were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg body weight). The entire heart was rapidly excised and rinsed in ice cold isotonic (0.9% wt/vol) saline to remove intraluminal blood. Hearts were blotted dry and weighed. Ventricles were isolated and then sectioned into right free wall, interventricular septum, and left free wall. Sections were quickly weighed, clamped frozen with aluminum tongs at the temperature of liquid nitrogen, wrapped in aluminum foil, and stored at Ϫ70°C until assayed.
Frozen samples of right and left ventricular free wall (ϳ50 mg each) were weighed and homogenized in nine volumes of various ice-cold buffers using a motor driven, ground glass homogenizer (Duall Type 22, Kontes Glass, Vineland, NJ). All assays were conducted in duplicate or triplicate on whole homogenates. Maximal enzyme activities were measured with a thermostatically controlled, double beam recording spectrophotometer (Lamda 6B UV/VIS, Perkin-Elmer, Norwalk, CT). Cuvettes and their contents (total volume was 1.0 mL) were brought to the assay temperature (25°Ϯ 0.5°C) with a thermostatically controlled water bath (Neslab RTE111, Newington, NH). In each case, substrate and cofactor concentrations were saturating and enzyme activity was linear for the duration of each assay (5 min). Enzyme activities are expressed as mol of substrate converted to product per minute per gram of tissue wet weight (U/g). All biochemical reagents and enzymes were of analytical grade and purchased from Sigma (St. Louis, MO). Homogenates were taken through a freeze-thaw cycle to disrupt mitochondrial membranes and then added to each cuvette. Assays were initiated by adding oxaloacetic acid (50 mmol/L final concentration) and production of free CoASH was monitored with DTNB by following the increase in absorbance at 412 nm.
Hexokinase (HK; EC 2.7.1.1)
This marker of anaerobic and aerobic glucose metabolism, was measured in homogenates diluted 1:20 (wt/vol) in 40 mmol/L HEPES, 1 mmol/L EDTA, 2 mmol/L MgCl 2 , and 2 mmol/L dithiothrieitol (DTT), pH 7.4. The HK assay was based on that described by Crabtree and Newsholme. 21 The reaction mixture consisted of 40 mmol/L HEPES, 0.8 mmol/L EDTA, 7.5 mmol/L MgCl 2 , 1.5 mmol/L KCl, 2.5 mmol/L ATP (2 Na), 10 mmol/L creatine phosphate (2 Na), 0.9 IU/mL creatine phosphokinase, 0.7 IU/mL glucose-6-phosphate dehydrogenase, and 0.4 mmol/L NADP ϩ , pH 7.4. Ventricular homogenate was added to the cuvette and the assay was started by adding d-glucose (1.0 mmol/L final concentration) and followed at 340 nm.
Statistical Analyses
All results are expressed as mean Ϯ SD. Ventricular weights were expressed relative to body weight. Body weights and cardiac weights were evaluated for differences among groups using a one-way analysis of variance (ANOVA). If the one-way ANOVA revealed a significant difference, the data were further analyzed using Tukey tests. For blood pressure measurements, a two-way ANOVA was used. Group and time interactions were assessed with the Tukey post hoc correction. The response to an oral glucose challenge was quantified in two ways: 1) comparison of the time course of the glucose, insulin, or free fatty acid response between captopril-treated and control SHR by two-way ANOVA (with the Tukey post hoc correction), wherein any time-group interaction would be further evaluated by t test; and 2) by calculating the area under the response curve (area under the curve) by triangulation for glucose, insulin, and free fatty acids, wherein the areas would be compared between treated and control SHR by t test. Differences in enzyme activities among groups and between the right and left ventricle were analyzed using a two-way ANOVA. When indicated, we performed post hoc analysis of the two-way ANOVA using multiple t tests with a modified Bonferroni correction (because we were comparing different tissues from the same animals, as well as treatment and strain differences), which adjusted the ␣-level to account for the familywise error. The ␣-level for the ANOVA and Tukey tests was set at 0.05 and for the t tests was set at 0.022. Figure 1 illustrates the body weight gain of experimental animals (n ϭ 24) over the 4-week treatment period. Although untreated WKY weighed significantly more than both SHR groups, it is apparent that SHR receiving captopril gained weight at a rate indistinguishable from that of animals drinking distilled water. Final body weights were 329 Ϯ 17 g, 328 Ϯ 20 g, and 488 Ϯ 48 g for untreated SHR, SHR treated with captopril, and WKY groups, respectively. At the end of the experimental period, relative mass of the left ventricle was 30% to 36% greater in untreated SHR than in WKY rats (P Ͻ .05), but there was no significant difference between hearts of captopril-treated SHR and WKY rats ( Table 1 ). The relative mass of the right ventricle was comparable among all three groups.
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RESULTS
Physical Characteristics of Experimental Animals
Systolic Blood Pressure
The blood pressure response to captopril treatment is shown in Figure 2 . Systolic blood pressure was significantly less in normotensive WKY rats and captopril-treated SHR than in untreated SHR at the end of the study. Furthermore, SHR receiving captopril had lower blood pressure throughout the treatment period than SHR controls. Namely, a significant two-way ANOVA and post hoc analysis revealed that blood pressure at all time points except one (day 26 [data not shown]) was lower in captopril-treated animals. Figure 3 illustrates the glucose, insulin, and free fatty acid (FFA) response to oral glucose tolerance testing. After 4 weeks of treatment, concentrations of glucose, insulin, and FFA after a brief fast were comparable between control and captopril-treated SHR, however, both insulin and FFA were significantly higher in both groups of SHR than (previously reported) WKY animals. After oral glucose, area under the glucose response curve was also not different between control SHR (414.2 Ϯ 49.9 mg/ dL ⅐ min) and captopril-treated SHR (422.8 Ϯ 78.8 mg/dL ⅐ min). Similarly, the area under the insulin response curve was comparable in the two groups, the control being 2.96 Ϯ 1.40 ng/mL ⅐ min and captopril being 3.42 Ϯ 1.95 ng/mL ⅐ min. Finally, there was no significant difference in the FFA response during the oral glucose tolerance test in control and captopriltreated SHR. Although the area under the FFA re- sponse curve to glucose appeared higher in captopriltreated SHR than in control SHR (2.75 Ϯ 0.58 v 1.86 Ϯ 0.42 Eq/mL ⅐ min), these differences were not statistically significant.
Metabolic Measurements
Enzyme Activities in Cardiac Ventricles
Differences in cardiac enzyme activities were found between right and left ventricles for each group of rats and between left ventricles of different groups (Table  2 ). In hearts of control SHR, the activity of HOAD was significantly (20%) higher in the right ventricle compared with left ventricle. HOAD activity was also 17% greater in the left ventricle of captopril-treated SHR than in normotensive WKY (P Ͻ .05). Citrate synthase activity was greater in the left ventricle in comparison to the right ventricle for both untreated and captopril SHR, but similar between right and left ventricles of WKY rats. Citrate synthase activity was also elevated in the left ventricle of untreated SHR compared with WKY rats. HK activity was greater in the left ventricle than in the right ventricle of all groups. In addition, HK activity was significantly lower (Ϫ12%) in the left ventricle of captopril-treated SHR than in WKY control animals.
DISCUSSION
Angiotensin converting enzyme inhibitors are in wide use as safe and effective antihypertensive agents because of their efficacy in lowering blood pressure without deleterious metabolic side effects. In the current study, we have demonstrated that short term treatment of young male SHR with captopril results in a prompt and sustained reduction in systolic blood pressure, as expected, 14 and a significant reduction of relative cardiac mass compared with those in untreated SHR. Hemodynamic improvements with captopril treatment may be explained by inhibition of the plasma renin-angiotensin system (RAS), 23 reduced local formation of angiotensin II, 24 and increased levels of bradykinin, a known vasodilator. 25 Notably, recent molecular studies demonstrate that plasma angiotensinogen concentration and cardiac angiotensinogen mRNA were increased significantly at 14 weeks of age in SHR compared with WKY, 26 providing evidence for the role of the RAS in promoting hypertension in SHR. Another potential benefit of treatment with captopril is a reduction in left ventricular hypertrophy. Similar to our results, several studies have demonstrated near normalization of relative total cardiac and left ventricle weight in captopril-treated SHR. 14, 27, 28 There is evidence suggesting that angiotensin II levels may modulate left ventricular hypertrophy in SHR 14 : namely, angiotensin II may directly stimulate growth of cardiac myocytes via AT1 receptors. 25 Treatment with ACE inhibitors can also improve perfusion capacity of the hypertrophied myocardium in SHR by promoting capillary proliferation. 29 This compensation should promote delivery of oxygen and nutrients and may ultimately improve cardiac function and metabolism.
Normally, cardiac metabolism is essentially aerobic and myocytes preferentially oxidize fatty acids for energy metabolism. 30 However, there is evidence that mild hypertension with normal left ventricular mass in humans 9 or hypertension with concomitant cardiac hypertrophy in dogs 7 and SHR 8 induces a shift in substrate preference from fatty acids to glucose and the glycolytic pathway. Based on our studies of cardiac enzymes in vitro, there are differences in energy metabolism between the right and left ventricles of young male SHR and WKY. It is also clear that both hypertension and the treatment of hypertension with captopril have significant effects on the biochemical profile and possibly the substrate preference of the left ventricle. Conversely, the right ventricle does not appear to undergo enzymatic shifts in response to genetic hypertension. Whereas maximal activities of CS are similar between the right and left ventricle of normotensive WKY, untreated SHR have relatively higher HOAD activity in their right ventricle and citrate synthase activity in their left ventricle. 3-Hydroxyacyl-CoA dehydrogenase is located on the inner mitochondrial membrane and participates in ␤-oxidation of fatty acids, whereas citrate synthase is an enzyme of the mitochondrial matrix and initiates the citric acid cycle. Interventricular differences in HOAD for untreated SHR may reflect lower fatty acid oxidation in their left versus right ventricle, although these HOAD activities were comparable to WKY values. Ventricular aerobic capacity per wet weight of tissue, as reflected by citrate synthase activity, was expanded slightly in the left ventricle of SHR, despite the increased cardiac size. The results confirm the preferential accumulation of mitochondrial protein during the early stages of cardiac hypertrophy in SHR and compensated weight-specific aerobic capacity. 31 Myocardial function, as assessed by contractility of papillary muscles, is normal or enhanced in SHR between 6 and 18 months of age relative to WKY. 32 Presumably, pressure overload produces a greater energy demand on the left ventricle and initially promotes synthesis of mitochondria for increased production of ATP. Conversely, the ventricle of the aged (18 to 24-month-old) SHR has a reduced mitochondrial complement relative to myofibrillar material 33 and impaired hemodynamic performance. 34 In the current study, HOAD was selectively increased and hexokinase decreased with left ventricular regression after captopril treatment, indicating an enhanced capacity for lipid oxidation and decreased handling of glucose for energy metabolism. According to predictions of the glucose fatty acid cycle, 35 an overabundance of circulating lipid fuels (FFA), as seen in SHR, should increase lipid oxidation for cardiac energy and reduce glucose use. It is possible that the slight increase in HOAD in captopril-treated left ventricle compared with that in control rats may reflect the slight, nonsignificant increase in circulating FFA seen in the captopril-treated rats, rather than an intrinsic effect of captopril on myocardial metabolism. Although FFA intake into myocardium reflects blood FFA, 36 it must be recalled that FFA available to cardiac cells for ␤-oxidation are derived from two sources: endogenous (triglyceride stores) and exogenous (albumin-bound FFA or triglyceride circulating in lipoprotein. 37 The relative contribution of these sources is unclear. In addition, Nuutila et al have recently described decreased rates of cardiac glucose uptake when FFA are elevated, 38 and it also appears that FFA in vivo impair oxidative, but not nonoxidative, glucose disposal. 39 Thus, although the observed increase in HOAD in captopril treatment may reflect elevated circulating FFA, it is unlikely that changes in intrinsic cardiac enzyme activity are noncontributory. It is unclear, however, how captopril treatment affects gene regulation of cardiac enzymes involved in fatty acid and glucose metabolism. Hexokinase is responsible for the phosphorylation of intracellular glucose and, along with glucose transport, is a putative rate-limiting step for use of glucose in cardiac muscle. 40 We found that left ventricular cardiac muscle of young captopril-treated SHR is characterized by reduced, not elevated, weight-specific hexokinase activity. Unlike previous studies, we therefore do not document a relative increase in cardiac glucose metabolism with hypertension. Paternostro et al 41 noted elevated basal glucose uptake and hexokinase activity, but no change in glucose transporter GLUT-1 mRNA and a decrease in GLUT-4 content in hearts from 16-to 18-month-old SHR compared with WKY. Conversely, these same investigators and others 42 provided evidence that insulin-stimulated glucose uptake in the heart is impaired in old (16-to 18-month-old) and young (8-week-old) SHR rats, respectively. The finding that cardiac hypertrophy increases glycolytic capacity in the heart of hypertensive rats may reflect a compensatory response to increasing diffusion distance between capillaries and myocytes. Given that we only measured maximal hexokinase activity in the current study, we cannot state unequivocally that glucose metabolism (glycolytic or aerobic catabolism) is reduced in the left ventricle of captopril-treated SHR. It is unclear whether cells reciprocally regulate fat and glucose oxidative capacities. On the other hand, studies in hindlimb-perfused animals suggest that increased FFA in the perfusate leads to impaired glucose use. 43 However, based on the concomitant increase in HOAD activity, we can postulate that there is a relative shift in energy metabolism from glucose to fatty acids in hearts of young male SHR receiving captopril. This metabolic result may have implications for promoting mitochondrial oxidation of fatty acids during cardiac regression and in the presence of elevated circulating FFA.
An important finding of the present investigation is that there was a dissociation between hemodynamic and metabolic effects with captopril treatment in young male SHR. Namely, in contrast to the hypotensive and cardiac effects of captopril in SHR, there was no improvement in glucose tolerance, insulinemia, or suppression of FFA after oral glucose. One serious limitation for metabolic studies is an alteration in growth rate because of the intervention. ACE inhibitors can suppress weight gain in growing SHR 44 ; however, in the current study, body weight gain was unaffected by captopril, suggesting that there was no deleterious effect on the overall health of the animals for the duration of treatment (4 weeks). In addition, maintenance of normal body weight allowed us to make metabolic comparisons without consideration of body weight as an important confounding factor. Compared with age-matched WKY, SHR exhibit fasting hyperinsulinemia and hyperlipidemia, plus insulin resistance as evidenced by elevated glucose, insulin, and FFA responses to an oral glucose challenge. 2 Although clinical studies have shown that treatment with captopril can increase insulin-stimulated glucose uptake in hypertensive subjects, 11, 12 a lack of beneficial metabolic effects has also been noted. 16, 17 Both essential hypertension in humans and genetic hypertension in rats are associated with elevated plasma lipids. However, similar to previous studies of ACE inhibition on blood lipids in humans 11 and SHR, 44 captopril had little or no effect on serum FFA in the current experiments. The failure of captopril to demonstrate any metabolic benefit in an animal model that we have described as manifesting insulin resistance, reduced glucose tolerance, and impaired suppression of FFA after glucose ingestion could reflect several possibilities. First, insulin resistance and hypertension in the SHR may not be related in the same manner as in humans. We have recently demonstrated a discordance between in vivo and in vitro insulin action in skeletal muscle of SHR, suggesting that differences in concentrations and vascular delivery of fuels may lead to impaired insulin action in vivo. 45 Indeed, Ben BachirLamrini et al 46 provided evidence that young male SHR have decreased vascularity and slow-to-fast twitch transitions in skeletal muscles. These changes modify contractile performance of the soleus 47 and may ultimately influence glucose tolerance and insulin action in vivo. Acute reductions in systemic blood pressure in SHR treated with captopril appear to be due entirely to a significant decrease in total peripheral resistance. More specifically, captopril induces vasodilation of skeletal musculature. 13 Given that increased vascular perfusion has been used as an explanation for enhanced insulin action, 48 one might predict that captopril should enhance delivery of glucose and insulin to skeletal muscle and enhance glucose disposal. However, we cannot exclude the possibility that captopril does not improve capillary blood flow or modify muscle fiber type in young male SHR to enhance peripheral glucose uptake and insulin sensitivity.
The age of experimental animals, duration of treatment, and timing of studies may have also curtailed any metabolic benefits of captopril. Young (10-weekold) animals were treated for a relatively short period of time (4 weeks) before being studied. It is possible that either initiation of treatment at a younger age or a longer period of treatment would have affected glucose tolerance and insulin action in vivo. It is also possible that the timing of metabolic studies relative to the last dose of captopril may be important. Recently, Carvalho et al 49 demonstrated that treatment of male Wistar rats with captopril (2 mg/kg body weight) orally just 6 h and 1 h before experiments improved intravenous insulin sensitivity along with autophosphorylation of the insulin receptor, phosphorylation of IRS-1, and IRS-1 association with PI 3-kinase in skeletal muscle. Promotion of these early steps of insulin action were also stimulated by administration of bradykinin. Given the relatively short half-life of captopril in hypertensive patients after oral administration (t 1/2 Ͻ 1 h), 10 and the diurnal period that our animals probably went without captopril (5 to 7 h), it is possible that metabolic effects, unlike antihypertensive effects, are not long lasting. Ultimately, the therapeutically effective dose of captopril for blood pressure lowering and cardiac regression may be different from the dose for metabolic benefits. Furthermore, the antihypertensive and metabolic effects of captopril may not be comparable between patients with essential hypertension and young laboratory rats with genetic hypertension.
In conclusion, short term captopril treatment was effective in lowering blood pressure, promoting cardiac regression, and increasing the capacity for fatty acid oxidation in the left ventricle of young male SHR. However, there were no corresponding metabolic improvements in oral glucose tolerance or insulin-induced suppression of FFA.
